Campbell Prostate Cancer + NCCN 2.2021 Flashcards

(88 cards)

1
Q

The American Brachytherapy Society guidelines suggest that prostate glands that are greater than ___ are technically more difficult to implant because of: ___ and ___;

___ can reduce prostate volumes by ___ % to optimize gland before brachytherapy

A

60cm
- increased frequency of pubic arch interference - large number of seeds required

Cytoreductive ADT
25% to 40%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Prostate volumes in excess of ___ may require ___ before RT to reduce volume of rectum or bladder exposed to radiation.

A

Neoadjuvant ADT for cytoreduction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Transurethral resection of the prostate (TURP) ____ (before or after?) external radiation, rather than after, may be advisable for men in, or at risk of, retention.

A

BEFORE radiation!

** post-treatment transurethral resection is performed, there may be a higher associated risk of incontinence (Polland et al., 2017), particularly after brachytherapy with up to 18% of men incontinent after TURP

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Contraindications to RT for prostate cancer

A

Previous radical pelvic irradition
Previous pelvic surgery: potentially trap bowel within pelvic field
PResence of substantial or susceptible bowel (hernia ex.)
Poor tissue healing (chronic steroid therapy)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Risk strat:

Very low

A

• T1c AND
• Gleason score ≤6/grade group 1 AND
• PSA <10 ng/mL AND
• Fewer than 3 prostate biopsy fragments/cores
positive, ≤50% cancer in each fragment/core AND
• PSA density <0.15 ng/mL/g

Imaging: NOT indicated

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Risk strat:

Low

A
  • T1–T2a AND
  • Gleason score ≤6/grade group 1 AND
  • PSA <10 ng/mL

Imaging: NOT indicated

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Risk strat:

Favorable intermediate

A
  • T2b–T2c OR
  • Gleason score 3+4=7/grade group 2 OR
  • PSA 10–20 ng/mL AND
  • Percentage of positive biopsy cores <50%

Imaging:
• Bone imaging: not recommended for staging
• Pelvic ± abdominal imaging: recommended if
nomogram predicts >10% probability of pelvic lymph node involvement

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Risk Strat:

Unfavorable intermediate

A

• T2b–T2c OR
• Gleason score 3+4=7/grade group 2 or Gleason
score 4+3=7/grade group 3 OR
• PSA 10–20 ng/mL

Imaging:

  • Bone imaging: recommended if T2 and PSA >10 ng/mL
  • Pelvic ± abdominal imaging: recommended if nomogram predicts >10% probability of pelvic lymph
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Risk strat:

High

A

• T3aOR
• Gleason score 8/grade group 4 or Gleason score
4 +5=9/grade group 5 OR
• PSA >20 ng/mL

Imaging:
• Bone imaging: recommended
• Pelvic ± abdominal imaging: recommended if
nomogram predicts >10% probability of pelvic lymph

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Risk strat:

Very high

A

• T3b–T4 OR
• Primary Gleason pattern 5 OR
• >4 cores with Gleason score 8–10/grade group 4
or 5

Imaging:
• Bone imaging: recommended
• Pelvic ± abdominal imaging: recommended if
nomogram predicts >10% probability of pelvic lymph

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Observation is most frequently employed in ___ .

General ffu consists of:

A

Men at low risk of prostate cancer death

Periodic PSA testing, clinical exam, use of imaging to monitor progression

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

SURVEILLANCE should be recommended as the best care option for ___ and preferable care option for ___ localized prostate cancer.

A

best for VERY LOW RISK

preferable for LOW RISK

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Death in men on active surveillance, most commonly from ___

A

Cardiovascular disease

** Rarely from prostate cancer

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Risk factors:

____ race found be associated withdverse pathologic outcomes such as positive surgical margins, upgrading, or upstaging.

A

African-American race

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

A history of ___ is significant and may reflect a germline disposition to prostate cancer.

A

A history of metastatic disease at a young age (<60) in a first-degree relative

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Advising men to ____ is the single most cost-effective health intervention in the entire edifice of medical practice.

A

QUIT SMOKING!

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Patients taking ___ in the SELECT trial had an increased risk of prostate cancer.

Patient consuming >=140 micrograms/day of supplemental ___ had 2.6 times greater disease-specific mortality.

A

Vitamin E

Selenium

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Lifestyle recommendations for active surveillance: ___

A
  1. Exercise regularly, and include vigorous activity if possible.
  2. Maintain a healthy weight.
  3. Stop smoking.
  4. Eat a vegetable- and grain-based diet; moderate red meat consump-
    tion, especially processed meats; if eating meat, rely on fish and
    skinless poultry.
  5. Limit saturated fat intake.
  6. Take vitamin D, 1000 to 2000 IU/day, especially during periods
    of reduced sunlight.
  7. Consider a low-dose statin.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

IMRT

A

Intensity-modulated radiation therapy

IMRT employs more complex, dynamic beam shapes wherein the intensity of radiation is varied across the beam (as opposed to uniform intensity across the beam in 3DCRT)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Low-dose-rate Brachytherapy

A

Permanent seed implantation: Delivers a dose over a number of weeks to months depending on the isotope chosen, hence the term low- dose-rate

125Iodine emits low-energy x-rays at 27 keV, with a half-life of 59.6 days.

103Palladium was introduced in 1986 because it has an energy spectrum similar to that of 125I, with 21-keV x-rays, but with a significantly shorter half-life of 17 days.

131Cesium, which emits x-rays at 30 keV (thereby offering dose characteristics similar to 125I)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

High-dose-rate Brachytherapy

A

Delivers short but high doses of radiation using temporary catheters

Hollow catheters are placed through the perineum into the prostate using the same procedure as for LDR brachytherapy

iridium-192 (192Ir)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Advantages of HDR vs. LDR Brachytherapy:

A

The use of catheters allows for more ready inclusion of extracapsular
disease and seminal vesicles, if desired.
• There is greater opportunity for dose optimization by modifying
dwell times and positions of the source within the catheters.
• The use of high doses per fraction has a potential biologic dose advantage for prostate cancer if a low alpha/beta ratio exists.
• No need for personnel to handle the radioactive source during
treatment.
• The use of a single source for all patients using a multipurpose
facility makes HDR brachytherapy potentially more cost-effective.
Potential disadvantages for HDR versus LDR brachytherapy include: • There are potential treatment inaccuracies caused by catheter and organ/patient movement between imaging and time of source insertion (during treatment planning) or between fractions, interobserver contouring variabilities, and effects of edemaThe relatively high activity and energy of the 192Ir source requires
availability of a shielded room for treatment delivery.
• There are less favorable pathologic response results from avail- able post-treatment biopsy studies

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Major acute toxicity of brachytherapy is ___

A

Obstructive and irritative uropathy

Low but non-negligible risk of need for temporary catheterization.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Relative contraindications to brachytherapy:

A

Large TURP defects, TURP within prior 3-6months
Factors assoc. with poor urinary outcomes or obstruction: Qmax < 10, IPSS >20, large median lobe
Prior pelvic RT
Connective tissue disease or IBD
Pubic arch interference
Lithotomy position
Rectal fistula or lack of TRUS access

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
The most important pathologic criteria predicting prognosis after radical prostatectomy are:
``` Gleason score Surgical margin status, Extracapsular extension Seminal vesicle invasion Lymph node involvement ```
26
Many men with clinical stage T3 disease have ____ and may not benefit from prostatectomy. Select (low-volume disease) may benefit because local control may be achieved in most.
Regional spread
27
The presence of ___ increases progression from 7% to 18-35% at 5 years.
Focal or established extracapsular extension
28
Radical prostatectomy alone can result in disease-free survival in ___ despite clinically advanced disease.
At least one-half of men at 8 to 10 years
29
____ therapy before radical prostatectomy does NOT appear to improve DSS or OS.
Neoadjuvant androgen deprivation (NAD) ** For locally advanced tumors (specifically cT3), current data, both retrospective and prospective, do not support a significant benefit of NAD before surgery
30
The use of adjuvant RT is associated with ___. Early use of ___ may be beneficial for advanced tumors at the time of biochemical recurrence in select patients.
A range of BDFS (biochemical disease free survival) from 50% to 88% at 5 years secondary therapy (RT or AD)
31
Men with seminal vesicle invasion who achieve a low PSA level (<0.3 ng/mL) after prostatectomy or have positive surgical margins may benefit more from ___. men with more advanced disease never reaching an undetectable PSA level generally constitute a poor prognostic group likely harboring ___.
Adjuvant RT. Unrecognized lymph node or distant disease.
32
Postradiation PSA “bounce” NOT ALL MEN ARE DESTINED FOR BIOCHEMICAL
Varied definition: elevated PSA of 0.1 ng/mL to 0.5 ng/mL over the prebounce PSA with a subsequent decrease in PSA. Occurred at a mean time of 9 months Associated with an improvement in biochemical recurrence–free survival compared with those who did not have a bounce
33
Patients selected for salvage RP must have the ff: ___
Biopsy-proven radiorecurrent prostate cancer At least 10 years of life expectancy Lack of identifiable metastasis on imaging PSA of less than 10 ng/mL
34
All current forms of hormonal therapy in PCA function by: ___
Reducing the ability of androgen to activate the AR ** by lowering androgen levels, decreasing conversion of testosterone to more potent DHT, or blocking androgen-AR binding
35
___ is overexpressed in 20-30% of CRPC metastases.
AR gene ** enhances response to low levels of endogenous androgens
36
AR mutations and splice variants: ___ predominant splice variant has been strongly associated with castration resistance and overall poor patient survival
AR-V7
37
GnRH agonists
Leuprolide Goserelin Triptorelin SOA: Pituitary MOA: Stimulates release of LH; feedback loop ultimately decreases LH production Mainstay of therapy for metastatic disease; leads to increase in FSH; considerable side effects
38
GnRH antagonists
Degarelix Abarelix Cetrorelix SOA: Pituitary MOA: Binds to receptors and blocks release of GnRH Prevents testosterone surge; leads to decrease in FSH; considerable side effects
39
Adrenal-targeting drugs
Ketoconazole Abiraterone Oreteronel (TAK-700) Galeterone SOA: Adrenal MOA: Decreases androgen production from steroid precursors by blocking cytochrome P450 enzymes Selective CYP17 inhibitors administered with low-dose prednisone; side effects can include hypertension, edema, and hypokalemia
40
1st generation AR antagonists
Flutamide Nilutamide Bicalutamide SOA: Prostate, PCA MOA: Nonsteroidal antiandrogen inhibits binding of testosterone and DHT to the AR Monotherapy not indicated; associated with gynecomastia
41
2nd generation AR antagonists
Enzalutamide Apalutamide SOA: Prostate, PCA MOA: Blocks AR, minimizes nuclear translocation of AR, and diminishes AR-mediated transcription Associated with falls, fatigue, and decreased appetite
42
5alpha-reductase inhibitors
Finasteride (type II isoenzyme inhibition) Dutasteride (type I and II isoenzyme inhibition) SOA: Prostate, PCA MOA: Inhibits the conversion of testosterone to DHT Commonly administered for BPH; not indicated for prostate cancer management
43
Four approaches for androgen blockade:
(1) surgical removal of the testicles (orchiectomy), 2) AR antagonism, (3) inhibition of LHRH and/or LH, and (4) inhibition of androgen synthesis
44
About one-quarter of men on ___ therapy note a delayed adaptation to darkness after exposure to bright illumination.
NIlutamide ** Effects reversible with cessation
45
Most common side effects of enzalutamide: ___
Fatigue, breast enlargement/tenderness, diarrhea, and hot flashes. ** Seizures were more common in men taking enzalutamide compared with placebo but occurred in less than 1%
46
Common side effects of apalutamide: ___
25% of men Experienced a rash, 12% experienced falls and fractures, and 8% had hypothyroidism
47
In a review of 24 trials involving more than 6600 patients, survival after therapy with ___ was equivalent to orchiectomy
An LHRH agonist *** flare of LH and testosterone levels, resulting in a severe, life-threatening exacerbation of symptoms, almost exclusively occurring in men with metastases in the spine or weight-bearing regions
48
Aminoglutethimide
Blocks production of aldosterone and cortisol. As the medical version of a total adrenalectomy, the use of this agent requires replacement of cortisone and fludrocortisone *** Side effects include anorexia, nausea, skin rash, lethargy, vertigo, hypothyroidism, and nystagmus.
49
Abiraterone side effects include: ___ which are due to: ___ and may be prevented by: ___
Hypokalemia, hypertension, and fluid overload Increase in the mineralocorticoids deoxycorticoste- rone and corticosterone Co-administration of prednisone (5 mg one to two times daily) suppresses the ACTH increase and lowers the likelihood of mineralocorticoid excess
50
LATITUDE trial showed that ___ + ___ was superior to traditional ADT by ___.
Abiraterone + prednisone was superior to traditional ADT Extending median radiographic progression-free survival and overall survival
51
VERY LOW RISK management | >20 y EPS
AS OR EBRT or brachytherapy OR RP - Adverse features: EBRT +- ADT or observation
52
VERY LOW RISK | 10-20 y EPS
AS
53
VERY LOW RISK | <10 y EPS
Observation
54
LOW RISK | >=10 y EPS
AS OR EBRT or brachytherapy OR RP - Adverse features: EBRT +- ADT or observation
55
LOW RISK | <10 y EPS
Observation
56
FAVORABLE INTERMEDIATE | >10 y
AS OR EBRT or brachytherapy ALONE OR RP +/- PLND if >= 2% prob of LN mets - AF, no LN: EBRT +- ADT or observation - LN mets: ADT (cat 1) +- EBRT (cat 2b) or observation
57
FAVORABLE INTERMEDIATE | 5-10 y EPS
EBRT or brachytherapy ALONE OR Observation
58
UNFAVORABLE INTERMEDIATE | >10 y EPS
RPp ± PLND if predicted probability of lymph node metastasis ≥2% OR EBRTo + ADTt (4–6 mo) or EBRTo + brachytherapyo ± ADTt (4–6 mo)
59
UNFAVORABLE INTERMEDIATE | 5-10 y EPS
EBRTo + ADTt (4–6 mo) or EBRTo + brachytherapyo ± ADTt (4–6 mo) OR Observation (PREFERRED)
60
HIGH/VERY HIGH RISK | > 5 y or symptomatic
EBRTo + ADTt (1.5–3 y; category 1) ± docetaxel (for very high risk only) OR EBRTo + brachytherapyo + ADTt (1–3 y; category 1 for ADT) OR RPp + PLND
61
HIGH/VERY HIGH RISK | ≤5 y and asymptomatic
Observationq or ADT or EBRT
62
Active surveillance (AS) components:
• Consider confirmatory prostate biopsy with or without mpMRI and with or without molecular tumor analysisj to establish candidacy for active surveillancen • PSA no more often than every 6 mo unless clinically indicated • DRE no more often than every 12 mo unless clinically indicated v • Repeat prostate biopsy no more often than every 12 mo unless clinically indicated • Repeat mpMRI no more often than every 12 mo unless clinically indicated
63
Observation
involves monitoring the course of disease with the expectation to deliver palliative therapy for the development of symptoms or a change in exam or PSA that suggests symptoms are imminent
64
Adverse features
Positive margin(s); seminal vesicle invasion; extracapsular extension; or detectable PSA
65
PSA nadir
PSA nadir is the lowest value reached after EBRT or brachytherapy
66
PSA persistence/recurrence after RP
Failure of PSA to fall to undetectable levels (PSA persistence) or undetectable PSA after RP with a subsequent detectable PSA that increases on 2 or more determinations (PSA recurrence).
67
RTOG-ASTRO (Radiation Therapy Oncology Group - American Society for Therapeutic Radiology and Oncology) Phoenix Consensus
1) PSA increase by 2 ng/mL or more above the nadir PSA is the standard definition for PSA persistence/ recurrence after EBRT with or without HT; and 2) A recurrence evaluation should be considered when PSA has been confirmed to be increasing after radiation even if the increase above nadir is not yet 2 ng/mL, especially in candidates for salvage local therapy who are young and healthy.
68
REGIONAL RISK GROUP (ANY T, N1,M0) | >5 y or symptomatic
EBRTo + ADTt (preferred) ± abirateroneee,ff OR ADTt ± abirateronet,ee
69
REGIONAL RISK GROUP (ANY T, N1,M0) ≤5 y and asymptomatic
Observationq or t | ADT
70
MONITORING: RECURRENCE | After initial definitive therapy
* PSA every 6–12 mo for 5 y,gg then every year * DRE every year, but may be omitted if PSA undetectable If with: Radiographic evidence of metastatic disease without PSA persistence/recurrence --> BIOPSY
71
MONITORING: RECURRENCE N1 on ADT or Localized on observation
* Physical exam + PSA every 3–6 mo * Imaging for symptoms or increasing PSAf Check for PROGRESSION: N1, m0 or m1
72
POST-RP PSA Persistence/recurrence
``` Risk stratificationjj PSADT Consider: • Bone imagingf,kk • Chest CT • Abdominal/pelvic CT or abdominal/pelvic MRIf • C-11 choline or F-18 fluciclovine PET/CT or PET/MRIf,w,ll • Prostate bed biopsy (especially if imaging suggests local recurrence ``` IF: Studies negative for distant metastases or imaging not performed --> EBRTo ± ADTt or Observationq --> then monitor for progression
73
PSA persistence/ recurrencey or | Positive DRE
``` • Risk stratificationmm PSADT • Bone imagingf,kk • Prostate MRI • Transrectal ultrasound (TRUS) biopsy • Consider: Chest CT Abdominal/pelvic CT or abdominal/ pelvic MRIf C-11 choline or F-18 fluciclovine PET/CT or PET/ MRIf,ll ``` TRUS biopsy positive, studies negative for distant metastases --> >10y LIFE EXPECTANCY -- > Observationq or p RP + PLND or o Brachytherapy or High-intensity focused ultrasound (HIFU) (category 2B) or cryotherapy TRUS negative or <10 y EPS: Observation or ADT
74
M0-CASTRATION NAIVE SYSTEMIC THERAPY
Observation OR ADT Then: Physical exam + PSA every 3–6 mo • Imaging for symptoms • Consider periodic imaging for patients with M1 to monitor treatment response
75
M1-CASTRATION NAIVE SYSTEMIC THERAPY
ADTt with one of the following: • Preferred regimens: Apalutamide (category 1)t Abiraterone (category 1)t,ee Docetaxel 75 mg/m2 for 6 cyclesuu (category 1)vv Enzalutamide (category 1)t • EBRTo to the primary tumor for low-volume M1uu or ADT Then: Physical exam + PSA every 3–6 mo • Imaging for symptoms • Consider periodic imaging for patients with M1 to monitor treatment response
76
M0-CRPC Conventional imaging studies negative for distant metastases
Continue ADTt to maintain castrate serum levels of testosterone (<50 ng/dL) PSADT >10 mo: Observation (preferred)q or Other secondary t hormone therapy ``` PSADT ≤10 mo: Preferred regimens: • Apalutamidet (category 1) • Darolutamidet (category 1) t • Enzalutamide (category 1) Other recommended regimens: • Other secondary t ```
77
M1-CRPC CRPC, conventional imaging studies positive for metastases
• • • Metastatic lesion biopsyyy Tumor testing for MSI-H or dMMR if not previouslyc performed Germline and tumor testing for homologous recombination gene mutations if not previously performedc • Continue ADTt to maintain castrate levels of serum testosterone (<50 ng/dL) • Additional treatment options: Bone antiresorptive therapy with denosumab (category 1, preferred) or zoledronic acid if bone metastases present o Palliative RT for painful bone metastases Best supportive care
78
SYSTEMIC THERAPY FOR M1 CRPC: ADENOCARCINOMA | NO PRIOR docetaxel/no prior novel hormone therapy
No prior docetaxel/no prior novel hormone therapyfff • Preferred regimens Abirateronet,ggg (category 1hhh) Docetaxelaaa,iii (category 1) Enzalutamidet (category 1) •Useful in certain circumstances Sipuleucel-Taaa,jjj (category 1) Radium-223kkk for symptomatic bone metastases (category 1) •Other recommended regimens t Other secondary hormone therapy
79
SYSTEMIC THERAPY FOR M1 CRPC: ADENOCARCINOMA | PRIOR docetaxel/no prior novel hormone therapy
• Preferred regimens Abirateronet, ggg (category 1) Cabazitaxelaaa Enzalutamidet (category 1) • Useful in certain circumstances Mitoxantrone for palliation in symptomatic patients who cannot tolerate other therapiesaaa Cabazitaxel/carboplatinaaa,nnn aaa Pembrolizumab for MSI-H or dMMR Radium-223kkk for symptomatic bone metastases (category 1) • Other recommended regimens Sipuleucel-Taaa,jjj t Other secondary hormone therapy
80
SYSTEMIC THERAPY FOR M1 CRPC: ADENOCARCINOMA | Prior novel hormone therapy/No prior docetaxel
Prior novel hormone therapy/No prior docetaxelfff,lll • Preferred regimens aaa Docetaxel (category 1) Sipuleucel-Taaa,jjj • Useful in certain circumstances mmm Olaparib for HRRm (category 1) Cabazitaxel/carboplatinaaa,nnn aaa Pembrolizumab for MSI-H or dMMR Radium-223kkk for symptomatic bone metastases (category 1) Rucaparib for BRCAmooo • Other recommended regimens Abirateronet,ggg ggg,ppp Abiraterone +t dexamethasone Enzalutamide Other secondary hormone therapy t
81
SYSTEMIC THERAPY FOR M1 CRPC: ADENOCARCINOMA | Prior docetaxel and prior novel hormone therapy
All systemic therapies are category 2B if visceral metastases are present) • Preferred regimens Cabazitaxelaaa (category 1hhh) Docetaxel rechallengeaaa,eee • Useful in certain circumstances hhh,mmm Olaparib for HRRm (category 1) Cabazitaxel/carboplatinaaa,nnn aaa Pembrolizumab for MSI-H or dMMR Mitoxantrone for palliation in symptomatic patients who cannot tolerate other therapiesaaa Radium-223kkk for symptomatic bone metastases (category 1hhh) Rucaparib for BRCAmooo • Other recommended regimens Abirateronet,ggg Enzalutamidet t
82
An extended PLND
removal of all node-bearing tissue from an area bound by the external iliac vein anteriorly, the pelvic sidewall laterally, the bladder wall medially, the floor of the pelvis posteriorly, Cooper's ligament distally, and the internal iliac artery proximally.
83
Men with high-volume, ADT-naïve, metastatic disease should be considered for ___
ADT and docetaxel
84
Immunotherapy considered for: ___
Men with Asymptomatic or minimally symptomatic mCRPC may consider immunotherapy.
85
Sipuleucel-T is only for: ___
nly for asymptomatic or minimally symptomatic, no liver metastases, life expectancy >6 months, ECOG performance status 0–1. Sipuleucel-T is not recommended for patients with small cell/ neuroendocrine prostate cancer.
86
Pembrolizumab (MSI-H or DMMR) only as ___.
subsequent Systemic therapy for patients with metastatic CRPC who have progressed through prior docetaxel and/or a novel hormone therapy.
87
For prevention of SREs in CRPC: ___ and ___
Denosumab (SUPERIOR) and zoledronic acid have been shown to prevent disease-related skeletal complications, which include fracture, spinal cord compression, or the need for surgery or RT to bone. Denosumab (preferred) is given subcutaneously every 4 weeks. Zoledronic acid is given intravenously every 3 to 4 weeks or every 12 weeks. Zoledronic acid is not recommended for creatinine clearance <30 mL/min.
88
Osteonecrosis of the jaw (ONJ)
Seen with both agents; risk is increased in patients who have tooth extractions, poor dental hygiene, or a dental appliance. referred for dental evaluation before starting either zoledronic acid or denosumab.